<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29015/pembrolizumab-survival-data-minority-of-patients-are-surviving-beyond-4-5-years-checkpoint-inhibitors-are-giving-treatment-options-that-we-never-had?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Pembrolizumab Survival Data: Minority Of Patients Are Sur...

Name: Pembrolizumab Survival Data: Minority Of Patients Are Sur...
Uploaded: 2019-06-04T01:58:03
Duration: 2 min 47 s
Description: Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had.

Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had

00:02:47

Annual Meeting

3 年 104 ビュー

共有追加報告 0 0

埋め込む (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29015/pembrolizumab-survival-data-minority-of-patients-are-surviving-beyond-4-5-years-checkpoint-inhibitors-are-giving-treatment-options-that-we-never-had?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

埋め込む (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/29015/pembrolizumab-survival-data-minority-of-patients-are-surviving-beyond-4-5-years-checkpoint-inhibitors-are-giving-treatment-options-that-we-never-had?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/29015/pembrolizumab-survival-data-minority-of-patients-are-surviving-beyond-4-5-years-checkpoint-inhibitors-are-giving-treatment-options-that-we-never-had?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

リンク (HTML):

<a href="https://oncologytube.com/v/29015?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190604015803_961d/video_190604015803_961d.jpg?cache=15669162711678829655">Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had</a>

リンク (BBCode):

[url=https://oncologytube.com/v/29015?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190604015803_961d/video_190604015803_961d.jpg?cache=15669162711678829655[/img]Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had[/url]

今すぐにサインインしてください!

永久的なリンク

フレンドリーURL (SEO)

現在の時刻 (SEO)

カテゴリー:

Non-Small Cell Lung Cancer

解説:

Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had.